Table 3.
Prognostic impact of type of TKI, stratified by type of EGFR mutation, controlling for age, WHO performance score and number of metastatic organs involved.
| TKI | Del19 |
L858R |
||||
|---|---|---|---|---|---|---|
| n | HR | 95% CI | n | HR | 95% CI | |
| Overall | ||||||
| Erlotinib | 115 | 1 | – | 98 | 1 | – |
| Gefitinib | 269 | 1.11 | 0.86–1.42 | 201 | 1.12 | 0.86–1.45 |
| Afatinib | 103 | 1.00 | 0.76–1.32 | 58 | 1.20 | 0.87–1.66 |
| Osimertinib | 167 | 0.82 | 0.60–1.12 | 98 | 1.02 | 0.73–1.41 |
| Brain metastases | ||||||
| Erlotinib | 60 | 1 | – | 36 | 1 | – |
| Gefitinib | 17 | 0.96 | 0.49–1.87 | 18 | 1.99∗ | 1.05–3.76 |
| Afatinib | 13 | 0.87 | 0.41–1.85 | 13 | 1.71 | 0.83–3.52 |
| Osimertinib | 50 | 0.54∗ | 0.30–0.99 | 26 | 1.60 | 0.80–3.20 |
TKI: tyrosine kinase inhibitor; HR: hazard ratio; CI: confidence interval; ∗: p-value < 0.05.